0000950170-24-090311.txt : 20240805 0000950170-24-090311.hdr.sgml : 20240805 20240805070545 ACCESSION NUMBER: 0000950170-24-090311 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240805 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240805 DATE AS OF CHANGE: 20240805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axsome Therapeutics, Inc. CENTRAL INDEX KEY: 0001579428 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 454241907 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37635 FILM NUMBER: 241173078 BUSINESS ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 BUSINESS PHONE: (212) 332-3241 MAIL ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 8-K 1 axsm-20240805.htm 8-K 8-K
0001579428false00015794282024-08-052024-08-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2024

 

 

Axsome Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37635

45-4241907

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One World Trade Center, 22nd Floor

 

New York, New York

 

10007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (212) 332-3241

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

 

AXSM

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2024, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2024 and provided an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

Description

99.1

Press Release dated August 5, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Axsome Therapeutics, Inc.

 

 

 

 

Date:

August 5, 2024

By:

/s/ Herriot Tabuteau, M.D.

 

 

Name:

Title:

Herriot Tabuteau, M.D.
President and Chief Executive Officer

 

 EX-99.1 2 axsm-ex99_1.htm EX-99.1 EX-99.1

img36028404_0.jpg 

Exhibit 99.1

 

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

 

Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth

 

Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth

 

Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth

 

NDA for AXS-07 in migraine resubmitted

 

Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation anticipated 2H 2024

 

Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024; target enrollment reached

 

Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 2H 2024

 

SUSTAIN Phase 3 trial of solriamfetol in shift work disorder initiated

 

NDA submission for AXS-14 in fibromyalgia expected 3Q 2024

 

NEW YORK, August 5, 2024 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced financial results for the second quarter of 2024.

 

“We delivered another robust quarter driven by focused commercial execution and continued pipeline advancement,” said Herriot Tabuteau, MD, CEO of Axsome Therapeutics. “We continue to see strong demand for Auvelity and increased commercial payer coverage by more than 22 million lives as of August 1st. The NDA for AXS-07 in migraine has been resubmitted, and we are tracking to submit the NDA for AXS-14 in fibromyalgia in the third quarter. Trials in four new indications for solriamfetol are now underway, and we remain on track to deliver topline results from the FOCUS Phase 3 trial in ADHD in the second half of this year. For our AXS-05 program in Alzheimer’s disease agitation, the ADVANCE-2 Phase 3 trial continues to progress, and the ACCORD-2 Phase 3 trial has reached target enrollment, positioning us to potentially report topline results for both of these pivotal trials in the second half of the year.”

 

Second Quarter 2024 Financial Highlights

 

•
Total net product revenue for the second quarter of 2024 was $87.2 million, representing 87% year-over-year growth. Total net product revenue for the comparable period in 2023 was $46.7 million.

 

•
Auvelity net product sales were $65.0 million for the second quarter of 2024, representing 135% year-over-year growth. Auvelity net product sales for the comparable period in 2023 were $27.6 million.

 

•
Sunosi net product revenue was $22.1 million for the second quarter of 2024, consisting of $21.5 million in net product sales and $0.6 million in royalty revenue associated with sales in out-licensed territories, representing 16% year-over-year growth. Sunosi net product revenue for the comparable period in 2023 was $19.1 million, consisting of $18.4 million in net product sales and $0.7 million in royalty revenue.

 

•
Total cost of revenue was $8.1 million for the second quarter of 2024. Total cost of revenue for the comparable period in 2023 was $4.6 million.

1

 

 

 

 

•
Research and development (R&D) expenses were $49.9 million for the second quarter of 2024, compared to $20.6 million for the comparable period in 2023. The increase was primarily related to the initiation and continuation of solriamfetol Phase 3 trials in major depressive disorder, ADHD, and binge eating disorder, ongoing trials of AXS-05 and AXS-12, manufacturing costs associated with AXS-07 and AXS-14, post-marketing commitments for Auvelity and Sunosi, and higher personnel costs, including non-cash stock-based compensation, due to organizational growth.

 

•
Selling, general, and administrative (SG&A) expenses were $103.6 million for the second quarter of 2024, compared to $78.9 million for the comparable period in 2023. The increase was primarily related to commercialization expenses largely driven by field force expansion and higher personnel costs, including non-cash stock-based compensation, due to organizational growth.

 

•
Net loss for the second quarter of 2024 was $79.3 million or $(1.67) per share, compared to a net loss of $67.2 million or $(1.54) per share for the comparable period in 2023. The net loss in the second quarter of 2024 reflects $26.0 million in non-cash charges.

 

•
Cash and cash equivalents totaled $315.7 million at June 30, 2024, compared to $386.2 million at December 31, 2023.

 

•
Shares of common stock outstanding were 47,801,578 at June 30, 2024.

 

Financial Guidance

 

•
Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

 

Commercial Highlights

 

Auvelity

 

•
Approximately 123,000 prescriptions were written for Auvelity in the second quarter of 2024, representing a 29% sequential increase versus the first quarter of 2024.

 

•
Payer coverage for Auvelity in the commercial channel increased from 48% of lives covered last quarter to 60% of lives covered as of August 1. The proportion of lives covered in the government channel (Medicare and Medicaid) remains at approximately 100%. Payer coverage for Auvelity across all channels is now at approximately 76% of all covered lives. Axsome expects coverage to continue to expand and evolve.

 

Sunosi

 

•
Approximately 45,000 prescriptions were written for Sunosi in the U.S. in the second quarter of 2024, representing an 8% increase versus the first quarter of 2024.

 

•
Sunosi maintains broad payer coverage in the commercial channel with 95% of lives covered. Currently 83% of total lives across all channels are covered.

 

 

2

 

 

 

Development Pipeline

 

Axsome is advancing an industry-leading neuroscience pipeline encompassing five innovative, late-stage, patent-protected product candidates for 9 serious psychiatric and neurologic conditions, which affect more than 140 million people in the U.S. alone. Recent and anticipated progress for key pipeline programs is summarized below.

 

AXS-05

 

AXS-05 (dextromethorphan-bupropion) is Axsome’s novel, oral, investigational NMDA receptor antagonist and sigma-1 agonist being developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for AD agitation.

 

•
Alzheimer’s Disease Agitation: Axsome is conducting the ADVANCE-2 study, a Phase 3, placebo-controlled, parallel group trial evaluating the efficacy and safety of AXS-05 in AD agitation. Patients completing ADVANCE-2 may enter a long-term open label safety extension trial. The Company anticipates topline results from the ADVANCE-2 trial in the second half of 2024.

 

Axsome is also conducting the ACCORD-2 study, a Phase 3, double-blind, placebo-controlled, randomized withdrawal trial evaluating the efficacy and safety of AXS-05 in AD agitation. The enrollment target for the ACCORD-2 trial has been met and the Company now anticipates topline results in the second half of 2024.

 

•
Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2024.

 

AXS-07

 

AXS-07 (MoSEIC™ meloxicam-rizatriptan) is Axsome’s novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine being developed for the acute treatment of migraine.

 

•
Migraine: The Company has resubmitted its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. The Company expects the NDA resubmission to be designated as Class 2, which would be subject to a six-month review.

 

•
Axsome is conducting the EMERGE study, a multicenter, Phase 3, single-group trial evaluating the efficacy and safety of AXS-07 for the acute treatment of migraine headache in adults with a prior inadequate response to an oral CGRP inhibitor. The Company anticipates topline results from the EMERGE trial in the second half of 2024.

 

AXS-12

 

AXS-12 (reboxetine) is Axsome’s novel, oral, potent, investigational highly selective norepinephrine reuptake inhibitor and cortical dopamine modulator being developed for the treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug designation for narcolepsy.

 

•
Narcolepsy: Axsome is conducting a Phase 3 open label safety extension trial of AXS-12 with topline results anticipated in the fourth quarter of 2024. AXS-12 has previously met the primary endpoints and demonstrated positive and statistically significant results in the completed SYMPHONY Phase 3 and CONCERT Phase 2 trials in patients with narcolepsy.

 

3

 

 

 

AXS-14

 

AXS-14 (esreboxetine) is Axsome’s novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.

 

•
Fibromyalgia: Pre-submission activities for the Company’s NDA for AXS-14 for the management of fibromyalgia are substantially complete. The Company expects to submit the NDA in the third quarter of 2024. AXS-14 has previously met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the management of fibromyalgia.

 

Solriamfetol

 

Solriamfetol is Axsome’s dopamine and norepinephrine reuptake inhibitor and TAAR1 agonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD).

 

•
Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol for the treatment of ADHD in adults. The Company anticipates topline results in the second half of 2024.

 

•
Major Depressive Disorder: Axsome is conducting the PARADIGM study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol for the treatment of MDD. The Company anticipates topline results in 2025.

 

•
Binge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol for the treatment of BED. The Company anticipates topline results in 2025.

 

•
Shift Work Disorder: Axsome has initiated the SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol for the treatment of SWD in adults. The Company anticipates topline results in 2026.

 

Business Update

 

•
In June 2024, Axsome announced that it has resolved patent litigation with Unichem Laboratories Ltd. (Unichem) seeking approval to market a generic equivalent of Sunosi in the United States. The Company entered into a settlement agreement with Unichem Laboratories Ltd., which permits Unichem to begin selling its generic version of Sunosi on June 30, 2042, or earlier under certain circumstances. The June 30, 2042 date is also subject to potential extension for pediatric exclusivity.

 

4

 

 

 

Anticipated Milestones

 

•
Regulatory:

 

o
AXS-14 for fibromyalgia, NDA submission (3Q 2024)

 

•
Clinical Trial Topline Results:

 

o
Phase 3 ADVANCE-2 trial of AXS-05 in Alzheimer’s disease agitation (2H 2024)

 

o
Phase 3 ACCORD-2 trial of AXS-05 in Alzheimer’s disease agitation (2H 2024)

 

o
Phase 3 open-label safety extension trial of AXS-12 in narcolepsy (2H 2024)

 

o
Phase 3 FOCUS trial of solriamfetol in ADHD in adults (2H 2024)

 

o
Phase 3 EMERGE trial of AXS-07 in patients with migraine with inadequate response to oral CGRP inhibitors (2H 2024)

 

o
Phase 3 PARADIGM trial of solriamfetol in major depressive disorder (2025)

 

o
Phase 3 ENGAGE trial of solriamfetol in binge eating disorder (2025)

 

o
Phase 3 SUSTAIN trial of solriamfetol in shift work disorder (2026)

 

•
Clinical Trial Initiations and Progress:

 

o
Pivotal Phase 2/3 trial of AXS-05 in smoking cessation, initiation (2024)

 

Conference Call Information

 

Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss second quarter 2024 financial results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). The live webcast can be accessed on the Investors page of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.

 

About Axsome Therapeutics, Inc.

 

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.

 

5

 

 

 

Forward Looking Statements

 

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of the Company’s Sunosi® and Auvelity® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company’s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to the Company’s special protocol assessment for the MOMENTUM clinical trial; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

 

6

 

 

 

Axsome Therapeutics, Inc.

Selected Consolidated Financial Data

 

Axsome Therapeutics, Inc.

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

 

 

 

June 30,
2024

 

 

December 31,
2023

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

315,657

 

 

$

386,193

 

Accounts receivables, net

 

 

120,342

 

 

 

94,820

 

Inventories, net

 

 

15,220

 

 

 

15,135

 

Prepaid and other current assets

 

 

11,808

 

 

 

8,115

 

Total current assets

 

 

463,027

 

 

 

504,263

 

Equipment, net

 

 

724

 

 

 

846

 

Right-of-use asset - operating lease

 

 

6,071

 

 

 

6,772

 

Goodwill

 

 

12,042

 

 

 

12,042

 

Intangible asset, net

 

 

50,107

 

 

 

53,286

 

Non-current inventory and other assets

 

 

16,255

 

 

 

11,027

 

Total assets

 

$

548,226

 

 

$

588,236

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

61,340

 

 

$

40,679

 

Accrued expenses and other current liabilities

 

 

116,771

 

 

 

90,501

 

Operating lease liability, current portion

 

 

1,419

 

 

 

1,267

 

Contingent consideration, current

 

 

7,040

 

 

 

6,407

 

Total current liabilities

 

 

186,570

 

 

 

138,854

 

Contingent consideration, non-current

 

 

69,620

 

 

 

73,300

 

Loan payable, long-term

 

 

179,330

 

 

 

178,070

 

Operating lease liability, long-term

 

 

6,829

 

 

 

7,035

 

Finance lease liability, long-term

 

 

3,025

 

 

 

—

 

Total liabilities

 

 

445,374

 

 

 

397,259

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding)

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value per share (150,000,000 shares authorized, 47,801,578 and 47,351,363 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively)

 

 

5

 

 

 

5

 

Additional paid-in capital

 

 

1,086,120

 

 

 

1,026,543

 

Accumulated deficit

 

 

(983,273

)

 

 

(835,571

)

Total stockholders’ equity

 

 

102,852

 

 

 

190,977

 

Total liabilities and stockholders’ equity

 

$

548,226

 

 

$

588,236

 

 

 

 

7

 

 

 

Axsome Therapeutics, Inc.

Consolidated Statements of Operations (Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

86,520

 

 

$

46,017

 

 

$

160,616

 

 

$

74,586

 

License revenue

 

 

—

 

 

 

—

 

 

 

—

 

 

 

65,735

 

Royalty revenue

 

 

646

 

 

 

683

 

 

 

1,549

 

 

 

955

 

Total revenues

 

 

87,166

 

 

 

46,700

 

 

 

162,165

 

 

 

141,276

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (excluding amortization and depreciation)

 

 

8,055

 

 

 

4,599

 

 

 

14,352

 

 

 

12,155

 

Research and development

 

 

49,853

 

 

 

20,581

 

 

 

86,683

 

 

 

38,374

 

Selling, general and administrative

 

 

103,554

 

 

 

78,935

 

 

 

202,524

 

 

 

153,126

 

Loss in fair value of contingent consideration

 

 

2,160

 

 

 

6,053

 

 

 

748

 

 

 

5,891

 

Intangible asset amortization

 

 

1,590

 

 

 

1,589

 

 

 

3,179

 

 

 

3,161

 

Total operating expenses

 

 

165,212

 

 

 

111,757

 

 

 

307,486

 

 

 

212,707

 

Loss from operations

 

 

(78,046

)

 

 

(65,057

)

 

 

(145,321

)

 

 

(71,431

)

Interest expense, net

 

 

(1,299

)

 

 

(2,730

)

 

 

(2,381

)

 

 

(4,994

)

Loss before income taxes

 

 

(79,345

)

 

 

(67,787

)

 

 

(147,702

)

 

 

(76,425

)

Income tax benefit (expense)

 

 

—

 

 

 

617

 

 

 

—

 

 

 

(1,963

)

Net loss

 

$

(79,345

)

 

$

(67,170

)

 

$

(147,702

)

 

$

(78,388

)

Net loss per common share, basic and diluted

 

$

(1.67

)

 

$

(1.54

)

 

$

(3.11

)

 

$

(1.80

)

Weighted average common shares outstanding, basic and diluted

 

 

47,573,229

 

 

 

43,669,820

 

 

 

47,482,602

 

 

 

43,597,131

 

 

 

Axsome Contacts:

Investors:

Mark Jacobson

Chief Operating Officer

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 212-332-3243

Email: mjacobson@axsome.com

www.axsome.com

 

Media:

Darren Opland

Director, Corporate Communications

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 929-837-1065

Email: dopland@axsome.com

www.axsome.com

8

 GRAPHIC 3 img36028404_0.jpg GRAPHIC begin 644 img36028404_0.jpg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end EX-101.SCH 4 axsm-20240805.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document And Entity Information
Aug. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 05, 2024
Entity Registrant Name Axsome Therapeutics, Inc.
Entity Central Index Key 0001579428
Entity Emerging Growth Company false
Entity File Number 001-37635
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-4241907
Entity Address, Address Line One One World Trade Center, 22nd Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10007
City Area Code (212)
Local Phone Number 332-3241
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol AXSM
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports axsm-20240805.htm axsm-20240805.xsd http://xbrl.sec.gov/dei/2024 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "axsm-20240805.htm": { "nsprefix": "axsm", "nsuri": "http://axsome.com/20240805", "dts": { "inline": { "local": [ "axsm-20240805.htm" ] }, "schema": { "local": [ "axsm-20240805.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_bf5adfb9-10d7-41de-94b7-badcbd85294a", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "axsm-20240805.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bf5adfb9-10d7-41de-94b7-badcbd85294a", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "axsm-20240805.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://axsome.com/20240805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-090311-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-090311-xbrl.zip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axsm-20240805_htm.xml IDEA: XBRL DOCUMENT 0001579428 2024-08-05 2024-08-05 0001579428 false 8-K 2024-08-05 Axsome Therapeutics, Inc. DE 001-37635 45-4241907 One World Trade Center, 22nd Floor New York NY 10007 (212) 332-3241 false false false false Common Stock, Par Value $0.0001 Per Share AXSM NASDAQ false